Argenx Se (ARGX) Total Liabilities (2015 - 2026)
Argenx Se (ARGX) posted quarterly Total Liabilities of $1.6 billion for Q2 2026, up 49.56% year-on-year from $1.1 billion in Q2 2025, and up 18.75% on a QoQ basis from $1.4 billion in Q4 2025.
Argenx Se (ARGX) Total Liabilities (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Total Liabilities for 12 consecutive years, with $1.6 billion the latest figure, recorded in Q2 2026.
- Quarterly Total Liabilities rose 49.56% year-over-year to $1.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.6 billion (up 49.56% YoY) and the FY2025 annual result came in at $1.4 billion, up 93.12% from the prior year.
- Total Liabilities climbed to $1.6 billion in Q2 2026 per ARGX's latest filing, from $1.4 billion in the prior quarter.
- Over the last five years, Total Liabilities for ARGX reached as high as $1.6 billion in Q2 2026 and fell as low as $279.0 million in Q2 2022.
- A 5-year average of $741.5 million and a median of $534.3 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities advanced 1.43% — and 2025, when it soared 102.1%.
- Year by year, Total Liabilities stood at $320.6 million in 2022, then jumped by 38.8% to $445.0 million in 2023, then surged by 58.27% to $704.2 million in 2024, then soared by 93.12% to $1.4 billion in 2025, then rose by 18.75% to $1.6 billion in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $1.6 billion, $1.4 billion, and $1.1 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 60.46 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 177.22 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 3.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 7.33 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 7.12 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.45 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.48 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.62 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 753.82 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 4.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.62 Bn |
| Dec 31, 2025 | 1.36 Bn |
| Jun 30, 2025 | 1.08 Bn |
| Dec 31, 2024 | 704.24 Mn |
| Jun 30, 2024 | 534.31 Mn |
| Dec 31, 2023 | 444.95 Mn |
| Jun 30, 2023 | 335.74 Mn |
| Dec 31, 2022 | 320.56 Mn |
| Jun 30, 2022 | 279.02 Mn |
| Dec 31, 2021 | 316.05 Mn |
| Jun 30, 2021 | 261.09 Mn |
| Dec 31, 2020 | 560.00 Mn |
| Jun 30, 2020 | 462.00 Mn |
| Dec 31, 2019 | 435.37 Mn |
| Jun 30, 2019 | 391.17 Mn |
| Dec 31, 2018 | 45.59 Mn |
| Jun 30, 2018 | 39.05 Mn |
| Dec 31, 2017 | 37.49 Mn |
| Jun 30, 2017 | 50.85 Mn |
| Dec 31, 2016 | 61.19 Mn |